Pediatrix Medical Group (NYSE:MD) Posts Quarterly Earnings Results, Beats Expectations By $0.07 EPS

Pediatrix Medical Group (NYSE:MD) released its earnings results on Thursday. The company reported $0.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.07, FiscalAI reports. Pediatrix Medical Group had a net margin of 8.96% and a return on equity of 20.05%. The company had revenue of $501.37 million for the quarter, compared to analyst estimates of $498.18 million. During the same period in the prior year, the firm earned $0.67 EPS. The firm’s quarterly revenue was up 1.7% on a year-over-year basis.

Here are the key takeaways from Pediatrix Medical Group’s conference call:

• Strong Q3 performance: Adjusted EBITDA reached $85 million, ahead of expectations, while same-unit revenue grew as volume and pricing each contributed positively. Management narrowed full-year 2026 adjusted EBITDA guidance to $290 million–$300 million.
• Shareholder returns and balance sheet: Pediatrix repurchased just over 3 million shares during the quarter, bringing cumulative buybacks since August 2025 to 10 million shares at an average price of $23. Net leverage remained below one times adjusted EBITDA, with $312 million of cash.
• Revenue tailwinds are moderating: The company is beginning to lap prior benefits from unusually strong collection activity, which reduced quarterly pricing growth by slightly more than 100 basis points. Operating costs continued to rise, although clinical salary growth remained relatively contained at roughly 3%–3.5%.
• Growth opportunities remain selective: Pediatrix is expanding telehealth and evaluating potential acquisitions in women’s and children’s healthcare, while monitoring 2027 OB hospitalist coding changes. Management said the No Surprises Act IDR process is unlikely to be a headwind because less than 5% of business is out-of-network.

Pediatrix Medical Group Stock Performance

MD traded up $0.59 during trading on Friday, hitting $29.77. The company’s stock had a trading volume of 425,549 shares, compared to its average volume of 783,205. The firm has a market cap of $2.42 billion, a PE ratio of 14.24 and a beta of 0.61. Pediatrix Medical Group has a one year low of $16.90 and a one year high of $30.55. The business’s 50 day simple moving average is $26.86 and its 200-day simple moving average is $23.82. The company has a quick ratio of 1.32, a current ratio of 1.32 and a debt-to-equity ratio of 0.45.

Analysts Set New Price Targets

A number of research firms have recently weighed in on MD. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $25.00 price target on shares of Pediatrix Medical Group in a report on Wednesday, August 5th. Truist Financial increased their target price on shares of Pediatrix Medical Group from $28.00 to $31.00 and gave the company a “hold” rating in a research note on Friday. Wall Street Zen raised Pediatrix Medical Group from a “buy” rating to a “strong-buy” rating in a research note on Sunday, September 13th. Weiss Ratings raised Pediatrix Medical Group from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, September 9th. Finally, UBS Group upped their target price on shares of Pediatrix Medical Group from $25.00 to $28.00 and gave the stock a “neutral” rating in a research note on Thursday, August 6th. One investment analyst has rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $27.20.

Key Headlines Impacting Pediatrix Medical Group

Here are the key news stories impacting Pediatrix Medical Group this week:

• Positive Sentiment: Pediatrix reported quarterly EPS of $0.72, above the consensus estimate of $0.65 and up from $0.67 in the prior-year quarter. Buybacks helped enhance per-share results. Pediatrix Medical Group Q3 2026: Buybacks Drive EPS Beat
• Positive Sentiment: Revenue totaled $501.37 million, beating the $498.18 million analyst forecast and increasing 1.7% year over year. The simultaneous revenue and earnings beats strengthened the market’s response. Pediatrix Medical Group Beats Q3 Earnings and Revenue Estimates
• Positive Sentiment: The company reported an 8.96% net margin and 20.05% return on equity, indicating continued profitability and solid capital efficiency. Pediatrix Medical Group Reports Third-Quarter Results
• Neutral Sentiment: Management discussed the results during the quarterly earnings call, which investors will review for additional details on operating trends, guidance and the outlook for Pediatrix’s physician-services business. Pediatrix Medical Group Q3 2026 Earnings Call Transcript

About Pediatrix Medical Group

Pediatrix Medical Group, Inc provides specialized physician-led healthcare services for women, infants and children. The company’s clinical offerings include neonatal and perinatal care, maternal-fetal medicine, pediatric medical subspecialties, pediatric hospitalist services and related services delivered in partnership with hospitals and healthcare systems.

Pediatrix-affiliated physicians and advanced practice providers generally work in hospital-based settings, including neonatal intensive care units, delivery rooms, pediatric units and outpatient practices.